Cell Culture Engineering IV: Improvements of Human Health

Front Matter....Pages i-vii
Introduction....Pages 1-2
Cultural and physiological factors affecting expression of recombinant proteins....Pages 3-9
Selecting and designing cell lines for improved physiological characteristics....Pages 11-16
Applications of improved stoichiometric model in medium design and fed-batch cultivation of animal cells in bioreactor....Pages 17-29
Diverse effects of essential ( n -6 and n -3) fatty acids on cultured cells....Pages 31-50
Enhancement effects of BSA and linoleic acid on hybridoma cell growth and antibody production....Pages 51-56
Growth rate suppression of cultured mammalian cells enhances protein productivity....Pages 57-64
Growth and interferon-γ production in batch culture of CHO cells....Pages 65-71
Metabolic and kinetic studies of hybridomas in exponentially fed-batch cultures using T-flasks....Pages 73-86
Adaptation of mammalian cells to non-ammoniagenic media....Pages 87-94
Effect of endogenous proteins on growth and antibody productivity in hybridoma batch cultures....Pages 95-102
Extracellular insulin degrading activity creates instability in a CHO-based batch-refeed continuous process....Pages 103-109
Low temperature cultivation — A step towards process optimisation....Pages 111-116
Induction of apoptosis in oxygen-deprived cultures of hybridoma cells....Pages 117-128
Maximization of recombinant protein yield in the insect cell/baculovirus system by one-time addition of nutrients to high-density batch cultures....Pages 129-138
Recombinant protein expression in a Drosophila cell line: comparison with the baculovirus system....Pages 139-144
Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells....Pages 145-155
Relationship between oxygen uptake rate and time of infection of Sf9 insect cells infected with a recombinant baculovirus....Pages 157-167
Optimization of vaccine production for animal health....Pages 169-176
Evaluation of monitoring approaches and effects of culture conditions on recombinant protein production in baculovirus-infected insect cells....Pages 177-186
The analysis of protein pharmaceuticals: Near future advances....Pages 187-194
The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin....Pages 195-208
Effect of lipid supplements on the production and glycosylation of recombinant interferon-γ expressed in CHO cells....Pages 209-215
Role of environmental conditions on the expression levels, glycoform pattern and levels of sialyltransferase for hFSH produced by recombinant CHO cells....Pages 217-221
Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines....Pages 223-228
Interaction of cell culture with downstream purification: a case study....Pages 229-242
Evaluation of membranes for use in on-line cell separation during mammalian cell perfusion processes....Pages 243-251
Vortex flow filtration of mammalian and insect cells....Pages 253-258
Automated imunoanalysis systems for monitoring mammalian cell cultivation processes....Pages 259-269
A direct computer control concept for mammalian cell fermentation processes....Pages 271-279
Automated monitoring of cell concentration and viability using an image analysis system....Pages 281-289
Software sensors for the monitoring of perfusion cultures: Evaluation of the hybridoma density and the medium composition from glucose concentration measurements....Pages 291-299
Design of a bubble-swarm bioreactor for animal cell culture....Pages 301-309
Cells and bubbles in sparged bioreactors....Pages 311-320
Quantitative investigations of cell-bubble interactions using a foam fractionation technique....Pages 321-328
Prediction of mechanical damage to animal cells in turbulence....Pages 329-335
Repeated-batch cultures of Baby Hamster Kidney cell aggregates in stirred vessels....Pages 337-349
Towards the development of a bioartificial pancreas: immunoisolation and NMR monitoring of mouse insulinomas....Pages 351-363
Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience....Pages 365-372
Back Matter....Pages 373-376